PharmatrophiX, Initially Funded by the Alzheimer's Drug Discovery Foundation, Announces Exclusive Global Collaboration with Elan
Promise of revolutionary orally-administered drugs to combat Alzheimer's began journey 8 years ago
"Finding a needle in a haystack - 4 molecules out of a million"
NEW YORK, Aug. 6 /PRNewswire-USNewswire/ -- New therapeutics funded by the Alzheimer's Dr...
NeurogesX Announces New PDUFA Date for Qutenza(TM) New Drug Application
SAN MATEO, Calif., Aug. 5 /PRNewswire-FirstCall/ -- NeurogesX, Inc. (Nasdaq: NGSX ), a biopharmaceutical company focused on developing and commercializing novel pain management therapies, today announced that the United States Food and Drug
Administration (FDA) has extended the Pr...
Shanghai ChemPartner and ELARA Pharmaceuticals Expand Drug Discovery Collaboration to a New Level
SHANGHAI, Aug. 4 /PRNewswire-Asia/ -- Shanghai ChemPartner Co., Ltd.,
(ChemPartner) a wholly owned subsidiary of ShangPharma Corporation, announced
today that it has moved its drug
discovery collaboration with ELARA
Pharmaceuticals to a new level. ChemPartner will provide fully integrated
DOR BioPharma Receives FDA Orphan Drug Designation for orBec(R) for the Treatment of Chronic Gastrointestinal GVHD
PRINCETON, N.J., Aug. 4 /PRNewswire-FirstCall/ -- DOR BioPharma, Inc., (OTC Bulletin Board: DORB) (DOR or the Company), a late-stage biopharmaceutical company, announced today that the Office of Orphan Products Development of the United States Food and Drug
Administration (FDA) has granted Or...
Palatin Technologies, Inc. Receives U.S. Patent Allowance for Heart Failure Drug Candidate
CRANBURY, N.J., Aug. 4 /PRNewswire-FirstCall/ -- Palatin Technologies, Inc. (NYSE Amex: PTN ) announced today that it has received a Notice of Allowance from the U.S. Patent and Trademark Office for its U.S. Patent Application Number 11/694,260, titled "Cyclic Natriuretic Peptide Constructs...
Biotech Hot in July Driven by Positive Drug Data and Acquisitions
SAN FRANCISCO, Aug. 3 /PRNewswire/ -- Biotech was "hot" in July driven by drug
data, positive drug
sales/earnings and partnering and M&A deals. As a result, the Burrill Biotech Select Index posted a solid monthly gain of 6.5 percent, mirroring the Dow and Nasdaq, which closed the mon...
Micromet Receives European Orphan Drug Designation for Treatment of Acute Lymphoblastic Leukemia with BiTE Antibody Blinatumomab
BETHESDA, Md., Aug. 3 /PRNewswire-FirstCall/ -- Micromet, Inc. (Nasdaq: MITI ), a biopharmaceutical company developing novel, proprietary antibodies for the treatment of cancer, inflammation and autoimmune diseases, today announced that it has received Orphan Drug
Designation from the Europ...
Stemline Therapeutics CEO to Present at IBC's New Frontiers in Cancer Drug Development Conference
NEW YORK, July 30 /PRNewswire/ -- Stemline Therapeutics, Inc., a clinical stage biopharmaceutical company and a leading developer of oncology compounds directed to cancer stem cell targets, today announced that the Company's CEO, Ivan Bergstein M.D. has been invited to present at the New Fron...
UCSF researchers help crack parasite genome, identify drug leads
Two UCSF research papers this week are marking major breakthroughs in the effort to tackle schistosomiasis (bilharzia), a tropical disease that infects more than 200 million people worldwide and causes long-term debilitating illness and occasional paralysis or death.
One paper documents a multi...
Cellular Dynamics International In-Licenses Key Patent Portfolio for Using Stem Cell-Derived Cells in Drug Testing
MADISON, Wis., July 15 /PRNewswire/ -- Cellular Dynamics International (CDI) today announced that it has exclusively in-licensed a US-issued patent portfolio on optimizing the stem cell differentiation selection process and on using heart cells (cardiomyocytes) in drug
New method may accelerate drug discovery for difficult diseases like Parkinson's
CAMBRIDGE, Mass. (July 13, 2009) Whitehead Institute scientists have developed a rapid, inexpensive drug-screening method that could be used to target diseases that until now have stymied drug
developers, such as Parkinson's disease. This technique uses baker's yeast to synthesize and screen the...
Novel drug discovery tool could identify promising new therapies for Parkinson's disease
Researchers funded by the National Institutes of Health have turned simple baker's yeast into a virtual army of medicinal chemists capable of rapidly searching for drugs to treat Parkinson's disease.
In a study published online today in Nature Chemical Biology , the researchers showed that the...
Shanghai ChemPartner and Agios Expand Integrated Drug Discovery Research Collaboration
SHANGHAI, July 9 /PRNewswire-Asia/ -- Shanghai ChemPartner Co., Ltd.,
(ChemPartner) a wholly owned subsidiary of ShangPharma Corporation, today
announces that it has expanded its integrated drug
collaboration with Agios, the first biopharmaceutical company dedicated to the
Funxional Successfully Completes Initial Clinical Trial of FX125L, an Anti-Inflammatory Drug With a Novel Mechanism of Action
CAMBRIDGE, England, July 8 /PRNewswire/ -- Funxional Therapeutics Ltd
(Funxional) has announced today the successful completion of the first Phase
I study with FX125L, an orally available small molecule which belongs to a
new therapeutic class named Broad Spectrum Chemokine Inhibitors (BSCIs)....
DOR BioPharma Announces Issuance of European Patent for its LPM(TM) Oral Drug Delivery Technology
PRINCETON, N.J., July 8 /PRNewswire-FirstCall/ -- DOR BioPharma, Inc. (OTC Bulletin Board: DORB) (DOR or the Company), a late-stage biopharmaceutical company, announced today that it has received a European patent which addresses its Lipid Polymer Micelle (LPM(TM)) technology for the improved oral...
New Drug Application for Exenatide Once Weekly Accepted for Review by FDA
SAN DIEGO, INDIANAPOLIS and CAMBRIDGE, Mass., July 7 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc., (Nasdaq: AMLN ), Eli Lilly and Company (NYSE: LLY ) and Alkermes, Inc. (Nasdaq: ALKS ) today announced that the New Drug
Application (NDA) for exenatide once weekly has been accepte...
Burnham Institute for Medical Research and Magellan BioScience Group, Inc. Announce Drug Discovery Collaboration
Magellan BioScience Group, Inc. (Magellan), a pioneer in innovative drug
development from marine sources, and investigators at the Burnham Institute for Medical Research at Lake Nona (Burnham) announced today that they will begin a multidisciplinary drug
discovery collaboration to identify novel ...
Particle Sciences and Microfluidics Collaborate to Share Formulation and Nanotechnology Expertise for Pharmaceutical Drug Product Development, Analysis and Commercialization
BETHLEHEM, Pa. and NEWTON, Mass., June 30 /PRNewswire/ -- Microfluidics, a wholly owned subsidiary of Microfluidics International Corporation (OTC Bulletin Board: MFLU), and Particle Sciences Inc. (PSI) have formed a strategic alliance to help biopharmaceutical companies leverage the most advanced...
Clavis Pharma Raises NOK 129 Million (USD 20 Million) in a Private Placement to Fund Further Development of its Pipeline of Novel Anticancer Drug Candidates
OSLO, Norway, June 26 /PRNewswire-FirstCall/ -- Clavis Pharma ASA (OSE:
CLAVIS) today announced that the Company has raised NOK 129 million
(equivalent to USD 20 million) in gross proceeds through a private placement
of 10,750,000 new shares, each with a par value of NOK 1.00 at a price of NOK...
Biovista Inc. Announces Positive Efficacy Results in a Pre-Clinical Trial of its BVA-601 Repositioned Drug for Epilepsy
CHARLOTTESVILLE, Virginia, June 23 /PRNewswire/ -- Biovista Inc. today
announced that BVA-601, its small-molecule drug
targeting epilepsy, has shown
positive results in the Kainic acid murine model of temporal lobe epilepsy.
BVA-601, an existing drug
that Biovista repositioned in epilepsy, exh...
Rules-Based Medicine, Inc. Launches DiscoveryMAP(TM) Service for Drug and Diagnostic Development
Nearly 200 Quantitative Immunoassays for Discovery and Validation of New Biomarker Panels
AUSTIN, Texas, June 17 /PRNewswire/ -- Rules-Based Medicine, Incorporated (RBM), the world's leading multiplexed biomarker testing laboratory, today announced the availability of the most comprehensive c...
FDA Appointed Arthritis Advisory Committee Recommends U.S. Food and Drug Administration Approval for KRYSTEXXA(TM) for Refractory Chronic Gout
Savient to Host Conference Call and Webcast on Wednesday, June 17 at 8:30 a.m. Eastern Time
EAST BRUNSWICK, N.J., June 16 /PRNewswire-FirstCall/ -- Savient Pharmaceuticals, Inc. (Nasdaq: SVNT ) announced today that the Arthritis Advisory Committee appointed by the U.S. Food and Drug
Covance to Present at the Drug Information Association's 45th Annual Meeting
- Covance experts to present best practices for improving drug
safety and reducing R&D time, cost -
PRINCETON, N.J., June 16 /PRNewswire-FirstCall/ -- Covance Inc. is pleased to announce the complete list of experts scheduled to present at the Drug
Information Association's (DIA) 45th A...
New Test from Quest Diagnostics Helps Physicians Choose HIV Antiretroviral Therapy in Patients with History of Drug Resistance
Faster reporting aids physicians in identifying HIV mutations that can inhibit effectiveness of newest class of antiretroviral therapy
MADISON, N.J., June 12 /PRNewswire-FirstCall/ -- Quest Diagnostics Incorporated (NYSE: DGX ), the world's leading provider of diagnostic testing, informatio...
MedNet Solutions to Introduce New EDC/eClinical Technologies at the 2009 Drug Information Association Annual Meeting
MINNETONKA, Minn., June 11 /PRNewswire/ -- MedNet Solutions, a global life sciences technology solutions company specializing in clinical study management systems, will unveil a variety of exciting new and enhanced eClinical technologies at the upcoming Drug
Information Association (DIA) Annual Me...
Jubilant to Work With Endo Pharmaceuticals on Drug Development
NOIDA, India, June 11 /PRNewswire/ --
- Collaboration to Provide Endo Pharmaceuticals With New Drug
Jubilant Organosys Ltd., headquartered in Noida, announced today that its
Bangalore-based subsidiary, Jubilant Biosys Ltd., has entered into a
discovery and ...
Strativa's New Drug Application for Ondansetron Orally Dissolving Film Strip Accepted by FDA
WOODCLIFF LAKE, N.J., June 10 /PRNewswire-FirstCall/ -- Strativa Pharmaceuticals, the proprietary products division of a wholly owned subsidiary of Par Pharmaceutical Companies, Inc. (NYSE: PRX ), today announced that the U.S. Food and Drug
Administration (FDA) has accepted its New Drug
PAREXEL Experts to Present Leading Insights at Drug Information Association 45th Annual Meeting
BOSTON, June 3 /PRNewswire-FirstCall/ -- Experts from PAREXEL International Corporation (Nasdaq: PRXL ), a leading global biopharmaceutical services provider, will address important industry issues at the Drug
Information Association (DIA) 45th Annual Meeting, being held from June 21 - 25, 2009 ...
Delcath Systems Granted Third Orphan Drug Designation
NEW YORK, June 2 /PRNewswire-FirstCall/ -- Delcath Systems, Inc. (Nasdaq: DCTH ), a medical technology company testing its proprietary treatment method for primary and metastatic cancers to the liver, announced today that the United States Food and Drug
Administration ("FDA") granted Delcath's a...
Vimpat(R) (lacosamide) C-V, a New Antiepileptic Drug (AED), To Be Available in U.S. Pharmacies
ATLANTA, May 26 /PRNewswire/ -- Vimpat (R) (lacosamide) C-V, a new antiepileptic drug
(AED), will be available in U.S. pharmacies by the first week of June 2009. Vimpat was approved by the U.S. FDA in the fall of 2008 for the use as an add-on therapy for the treatment of partial-onset seizures i...
Beactica Announces Drug Discovery Agreement With Cubist Pharmaceuticals
UPPSALA, Sweden, May 25 /PRNewswire/ -- Beactica AB, the Swedish
discovery company, today announced that it has entered
into an agreement with Cubist Pharmaceuticals, Inc. (Lexington, MA; NASDAQ:
CBST ). Under the agreement, Beactica will use its Sprint(TM) surface plasmo...
Solvay Pharmaceuticals Announces Strategic Partnership With HUYA to Access new Drug Candidates From China
BRUSSELS , May 18 /PRNewswire/ -- Solvay Pharmaceuticals announces it has signed an agreement with HUYA Bioscience International, a company specialized in enabling and accelerating global codevelopment of novel biopharmaceutical product opportunities originating in China.
Through this agree...
Scotland Highlights New Partnerships and Cutting-Edge Drug Discovery Research
Recent stem cell advances and Sir Philip Cohen's groundbreaking research into new drug
targets showcase Scotland's life sciences innovation at BIO 2009
ATLANTA, May 18 /PRNewswire/ -- At this year's BIO International Convention, May 18-21 in Atlanta, Scotland will showcase the commercial s...
U.S. FDA Accepts Aridol(TM) New Drug Application for Review
SYDNEY, Australia, May 13 /PRNewswire-Asia/ -- Pharmaxis (ASX: PXS;
Nasdaq: PXSL ) today announced it had received notification from the United
States Food and Drug
Administration (FDA) that the New Drug
for its mannitol bronchial challenge test Aridol(TM) has been accepted...
Follica Appoints Drug Development and Dermatology Veteran, William D. Ju, as Chief Executive Officer
BOSTON, May 13 /PRNewswire/ -- Follica Inc., a privately held developer of novel therapies for androgenetic alopecia and other hair follicle and skin disorders, today announced that William D. Ju, M.D. has been appointed as president and chief executive officer. Dr. Ju succeeds Daphne Zohar, mana...
Sinobiopharma Announces SFDA Approval of Anti-Hypertension Drug Perindopril
NANTONG CITY, China, May 11 /PRNewswire-FirstCall/ -- Sinobiopharma, Inc. (OTC Bulletin Board: SNBP) ("Sinobiopharma" or, the "Company") is pleased to announce that it has received approval from the Chinese State Food and Drug
Administration (SFDA) to manufacture and market its formulation of Peri...
Successful Phase I/II Clinical Trial Results From Cancer Patients Treated With Anti-Cancer Drug From Axelar AB
STOCKHOLM, May 6 /PRNewswire/ -- Axelar AB today announced successful
completion of the single-day oral dosing part of its ongoing phase I/II
clinical trial on cancer patients with its new anti-cancer drug
insulin-like growth factor-1 (IGF-1) receptor inhibitor which has no effects
Sequella Commences Phase 1B Study for New Tuberculosis Drug SQ109
ROCKVILLE, Md., May 5 /PRNewswire/ -- Sequella, Inc., a clinical-stage biopharmaceutical company focused on diseases of epidemic potential, announced today the start of its Phase 1B trial for SQ109 with the dosing of the first cohort of volunteers. SQ109, a new diamine antibiotic intended to repla...
Exenatide Once Weekly New Drug Application Submitted to FDA for Type 2 Diabetes
SAN DIEGO, INDIANAPOLIS, and CAMBRIDGE, Mass., May 5 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc., (Nasdaq: AMLN ), Eli Lilly and Company (NYSE: LLY ) and Alkermes, Inc. (Nasdaq: ALKS ) today announced that a New Drug
Application (NDA) for exenatide once weekly has been submitted...
First oral uveitis drug reduces both inflammation and recurrence in potentially blinding eye disease
Fort Lauderdale, FL (May 4, 2009): Uveitis, or inflammation within the eye, is a group of diseases responsible for years of visual loss roughly comparable to that caused by diabetes. Now, results from a pioneering international Phase 3 program in uveitis, the LUMINATE trials sponsored by Lux Biosc...